Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
Introduction: Development of immune-related adverse events (irAEs) has been associated with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains unknown whether such an association exists in advanced hepatocellular carcinoma (aHCC). This study aims to evaluate the associ...
Saved in:
Main Authors: | Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Ailica Wan Xin Lee, Andrea Jing Shi Ang, Lawrence Wen Jun Wong, Su Pin Choo, David Wai-Meng Tai, Joycelyn Jie Xin Lee |
---|---|
Format: | article |
Language: | EN |
Published: |
Karger Publishers
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/496d27c9aa9f4d5e9ef0778f2382933a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021) -
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
by: Pan Shen, et al.
Published: (2021) -
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
by: Rosaria De Filippi, et al.
Published: (2021) -
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
by: Yi-Dan Yan, et al.
Published: (2021) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021)